Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Down 6.4% in October

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 192,700 shares, a drop of 6.4% from the September 30th total of 205,900 shares. Based on an average daily volume of 535,500 shares, the days-to-cover ratio is presently 0.4 days. Approximately 1.3% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Aptose Biosciences in a research report on Monday, October 28th. They set a “hold” rating for the company. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Institutional Trading of Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC purchased a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Price Performance

Shares of NASDAQ:APTO opened at $0.38 on Friday. The firm has a market capitalization of $6.90 million, a PE ratio of -0.09 and a beta of 1.26. The company has a 50-day moving average price of $0.38 and a two-hundred day moving average price of $0.70. Aptose Biosciences has a twelve month low of $0.33 and a twelve month high of $3.32.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.15.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.